Oklo (OKLO +1.29%), a small modular nuclear reactor start-up, recently secured critical government approvals for its major initiatives, yet its stock has plummeted by 20% since the announcement. The U.S. Department of Energy approved the Nuclear Safety Design Agreement for its Groves Isotopes Test Reactor in Texas, alongside its first-ever materials license from the Nuclear Regulatory Commission for handling nuclear isotopes. Additionally, Oklo’s Idaho Aurora Powerhouse project received safety approval, paving the way for future developments.
Despite these regulatory milestones, Wall Street remains skeptical, primarily due to the lack of commercial operating approval from the NRC for the Aurora Powerhouses, which is vital for Oklo’s business model. While the recent approvals enhance the likelihood of obtaining that crucial NRC approval, investors should remain cautious given the speculative nature of Oklo’s stock.
For market professionals, Oklo’s current share price below $50 may present a compelling entry point, especially as regulatory progress continues, but the path to profitability remains uncertain.
Source: fool.com